The New England Journal of Medicine published results from a nearly 11-year follow-up study, that showed an estimated overall survival rate of 83.3 percent.
Amgen announced positive results from a planned overall survival interim analysis of the Phase III head-to-head ENDEAVOR trial.
In a large-scale study published today in the journal Obstetrics and Gynecology, researchers found that nearly half of women from racial minorities receive cervical-cancer care that doesn't meet national standards.
A drug first designed to prevent cancer cells from multiplying has a second effect: it switches immune cells that turn down the body's attack on tumors back into the kind that amplify it. This is the finding of a study led by researchers from NYU Langone Medical Center and published recently in Cancer Immunology Research.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
Researchers at the University of Pittsburgh School of Medicine have uncovered a novel genetic mechanism of thyroid cancer, as well as a marker that may predict response to a particular class of drugs, not just in patients with thyroid cancer, but in those with many other types of cancer as well.
Researchers in the Schools of Medicine and Engineering at Vanderbilt University have discovered a proteomic “signature” from the airways of heavy smokers that could lead to better risk assessment and perhaps new ways to stop lung cancer before it starts.
Researchers at the Fred Hutchinson Cancer Research Center and the University of Washington say a new study suggests ways to improve immune therapy for certain cancers including a virus-associated form of Merkel cell carcinoma, a rare, aggressive skin cancer.
An analysis of a patient's deadly brain tumor helped doctors at the Yale Smilow Cancer Hospital identify new emerging mutations and keep a 55-year old woman alive for more than five years, researchers report in the journal Genome Medicine.
TapImmune Inc. said Memorial Sloan Kettering Cancer Center successfully completed the first safety cohort in its phase II ovarian cancer study.
